PURPOSE: We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment. MATERIALS AND METHODS: Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m(2) intravenous infusion on day 1 and intravenous ifosfamide 3 g/m(2) with Mesna uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks. RESULTS: One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2 approximately 6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3 approximately 4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3 approximately 21.7%). The median time to disease progression was 2.65 months (range: 2.02 approximately 3.20 months), and the median survival was 5.24 months (range: 2.99 approximately 7.49 months). CONCLUSION: Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.
PURPOSE: We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment. MATERIALS AND METHODS: Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m(2) intravenous infusion on day 1 and intravenous ifosfamide 3 g/m(2) with Mesna uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks. RESULTS: One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2 approximately 6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3 approximately 4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3 approximately 21.7%). The median time to disease progression was 2.65 months (range: 2.02 approximately 3.20 months), and the median survival was 5.24 months (range: 2.99 approximately 7.49 months). CONCLUSION: Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.
Authors: K Sommer; S O Peters; I H Robins; M Raap; G J Wiedemann; S Remmert; P Sieg; C Bittner; T Feyerabend Journal: Int J Oncol Date: 2001-06 Impact factor: 5.650
Authors: H Kunitoh; Y Akiyama; H Kusaba; N Yamamoto; I Sekine; Y Ohe; K Kubota; T Tamura; T Shinkai; T Kodama; K Goto; S Niho; Y Nishiwaki; N Saijo Journal: Lung Cancer Date: 2001 Aug-Sep Impact factor: 5.705
Authors: L C Pronk; D Schrijvers; J H Schellens; E A de Bruijn; A S Planting; D Locci-Tonelli; V Groult; J Verweij; A T van Oosterom Journal: Br J Cancer Date: 1998 Impact factor: 7.640
Authors: T Cerny; S Kaplan; N Pavlidis; P Schöffski; R Epelbaum; J van Meerbeek; J Wanders; H R Franklin; S Kaye Journal: Br J Cancer Date: 1994-08 Impact factor: 7.640
Authors: Byoung Yong Shim; Chi Hong Kim; So Hyang Song; Meyung Im Ahn; Eun Jung Hong; Sung Whan Kim; Suzy Kim; Min Seop Jo; Deog Gon Cho; Kyu Do Cho; Jinyoung Yoo; Hoon-Kyo Kim Journal: Cancer Res Treat Date: 2005-12-31 Impact factor: 4.679